Best Low-Debt Stocks to Buy

Apogee Therapeutics exhibits exceptional 10x growth potential, with recent developments significantly strengthening its thesis. The positive 16-week Phase 2 APEX data for zumilokibart in atopic dermatitis validates its potential as a best-in-class therapy in a multi-billion dollar market. Crucially, the $1.3 billion strategic financing collaboration with Blackstone Life Sciences dramatically de-risks its financial runway, extending it well beyond prior projections and supporting its clinical and commercialization efforts. While pre-revenue with expected net losses, its robust cash position (~$1.3B + Blackstone) provides ample capital. Leadership consistently delivers on milestones, fostering high conviction for substantial market re-rating as it approaches BLA submission and commercialization, despite some insider selling.

Atour Lifestyle Holdings Ltd (ATAT) maintains its strong trajectory as a high-growth, high-potential investment. The company's Q4 and FY 2025 results underscore its exceptional performance, with revenue growth exceeding 35% YoY and strong profitability (16.58% net margin, 46.96% ROE). Its scalable 'manachised' model continues to drive rapid network expansion and market leadership in China's premium lifestyle hotel segment, significantly expanding its total addressable market. The recent disclosure of Norges Bank's substantial stake further validates institutional confidence. While regulatory risks for Chinese ADRs persist, ATAT's consistent execution, asset-light model, and commitment to shareholder returns via its dividend policy position it strongly for continued market share gains and potential 10x growth within 3-5 years, especially with its burgeoning retail business adding diversification.